These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

962 related items for PubMed ID: 30449789

  • 1. Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis.
    Sakamoto N, Ishimoto H, Nakashima S, Yura H, Miyamura T, Okuno D, Hara A, Kitazaki T, Kakugawa T, Ishimatsu Y, Satoh M, Mukae H.
    Intern Med; 2019 Mar 15; 58(6):837-841. PubMed ID: 30449789
    [Abstract] [Full Text] [Related]

  • 2. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.
    Yamaguchi K, Yamaguchi A, Kashiwagi C, Sawada Y, Taguchi K, Umetsu K, Oshima K, Uchida M, Suzuki M, Kono S, Takemura M, Masubuchi H, Kitahara S, Hara K, Maeno T, Motegi SI, Muro Y, Sakairi T, Hisada T, Kurabayashi M.
    Respir Med; 2018 Jul 15; 140():1-5. PubMed ID: 29957268
    [Abstract] [Full Text] [Related]

  • 3. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis.
    Sakamoto S, Okamoto M, Kaieda S, Fujimoto K, Nagata S, Tominaga M, Nakamura M, Zaizen Y, Nouno T, Koga T, Kawayama T, Kuwana M, Ida H, Hoshino T.
    Respir Investig; 2018 Nov 15; 56(6):464-472. PubMed ID: 30150008
    [Abstract] [Full Text] [Related]

  • 4. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
    Fujisawa T, Hozumi H, Yasui H, Suzuki Y, Karayama M, Furuhashi K, Enomoto N, Nakamura Y, Inui N, Suda T.
    J Rheumatol; 2019 Aug 15; 46(8):935-942. PubMed ID: 31092718
    [Abstract] [Full Text] [Related]

  • 5. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.
    Ye Y, Fu Q, Wang R, Guo Q, Bao C.
    J Clin Lab Anal; 2019 Oct 15; 33(8):e22978. PubMed ID: 31301087
    [Abstract] [Full Text] [Related]

  • 6. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease.
    Motegi SI, Sekiguchi A, Toki S, Kishi C, Endo Y, Yasuda M, Ikeuchi H, Sakairi T, Hara K, Yamaguchi K, Maeno T, Hiromura K, Ishikawa O.
    Eur J Dermatol; 2019 Oct 01; 29(5):511-517. PubMed ID: 31617496
    [Abstract] [Full Text] [Related]

  • 7. A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment.
    Koichi Y, Aya Y, Megumi U, Shunichi K, Masafumi S, Hiroaki M, Masahiko K, Shinsuke K, Manabu U, Kenichiro H, Fumiaki A, Nozomi A, Toshitaka M, Masayoshi Y, Chikako K, Yoshinao M, Tatsuo S, Masahiko K.
    Mod Rheumatol; 2017 May 01; 27(3):536-540. PubMed ID: 25698373
    [Abstract] [Full Text] [Related]

  • 8. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis.
    Chen Z, Cao M, Plana MN, Liang J, Cai H, Kuwana M, Sun L.
    Arthritis Care Res (Hoboken); 2013 Aug 01; 65(8):1316-24. PubMed ID: 23908005
    [Abstract] [Full Text] [Related]

  • 9. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis.
    Matsushita T, Mizumaki K, Kano M, Yagi N, Tennichi M, Takeuchi A, Okamoto Y, Hamaguchi Y, Murakami A, Hasegawa M, Kuwana M, Fujimoto M, Takehara K.
    Br J Dermatol; 2017 Feb 01; 176(2):395-402. PubMed ID: 27452897
    [Abstract] [Full Text] [Related]

  • 10. Comparison of characteristics and anti-MDA5 antibody distribution and effect between clinically amyopathic dermatomyositis and classic dermatomyositis: a retrospective case-control study.
    Ji Q, Pan W, Zhang D, Hou Y, Wang Z.
    Front Immunol; 2023 Feb 01; 14():1237209. PubMed ID: 38098481
    [Abstract] [Full Text] [Related]

  • 11. Anti-Melanoma Differentiation-Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis.
    Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R.
    Arthritis Care Res (Hoboken); 2016 May 01; 68(5):689-94. PubMed ID: 26414240
    [Abstract] [Full Text] [Related]

  • 12. Rapidly progressive interstitial lung disease due to anti-MDA5 antibodies without skin involvement: a case report and literature review.
    González-Moreno J, Raya-Cruz M, Losada-Lopez I, Cacheda AP, Oliver C, Colom B.
    Rheumatol Int; 2018 Jul 01; 38(7):1293-1296. PubMed ID: 29417209
    [Abstract] [Full Text] [Related]

  • 13. Predictors of Poor Outcome of Anti-MDA5-Associated Rapidly Progressive Interstitial Lung Disease in a Chinese Cohort with Dermatomyositis.
    Li Y, Li Y, Wu J, Miao M, Gao X, Cai W, Shao M, Zhang X, Xu Y, Cong L, He J, Sun X.
    J Immunol Res; 2020 Jul 01; 2020():2024869. PubMed ID: 33299896
    [Abstract] [Full Text] [Related]

  • 14. Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review.
    Huang K, Vinik O, Shojania K, Yeung J, Shupak R, Nimmo M, Avina-Zubieta JA.
    Rheumatol Int; 2019 Nov 01; 39(11):1971-1981. PubMed ID: 31375890
    [Abstract] [Full Text] [Related]

  • 15. Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140/MDA5 antibody positive amyopathic dermatomyositis.
    Takada T, Aoki A, Asakawa K, Sakagami T, Moriyama H, Narita I, Sato S.
    Respir Med; 2015 Sep 01; 109(9):1174-80. PubMed ID: 26187000
    [Abstract] [Full Text] [Related]

  • 16. Early initiation of plasma exchange therapy for a patient with anti-MDA5 autoantibody-positive dermatomyositis developing rapidly progressive interstitial lung disease.
    Sasaki N, Ishii A, Kurabayashi T, Sugiyama M, Izumi Y, Nakagome Y, Hirano K, Sasaki S, Kondo Y, Nogi S, Nishikawa A, Hosono Y, Yamada C, Sato S.
    Mod Rheumatol Case Rep; 2021 Jan 01; 5(1):87-94. PubMed ID: 33048020
    [Abstract] [Full Text] [Related]

  • 17. Anti-MDA5 antibody-positive hypomyopathic dermatomyositis complicated with pneumomediastinum.
    Yashiro M, Asano T, Sato S, Kobayashi H, Watanabe H, Miyata M, Migita K.
    Fukushima J Med Sci; 2018 Jan 01; 64(2):89-94. PubMed ID: 30158335
    [Abstract] [Full Text] [Related]

  • 18. Association of Serum Soluble CD163 with Polymyositis and Dermatomyositis, Especially in Anti-MDA5 Antibody-positive Cases.
    Kawasumi H, Katsumata Y, Nishino A, Hirahara S, Kawaguchi Y, Kuwana M, Yamanaka H.
    J Rheumatol; 2018 Jul 01; 45(7):947-955. PubMed ID: 29657141
    [Abstract] [Full Text] [Related]

  • 19. Anti-MDA5 positive dermatomyositis complicated with rapidly progressive interstitial lung disease - a case report.
    De Backer E, Gremonprez F, Brusselle G, Depuydt P, Van Dorpe J, Van Haverbeke C, Goeminne PC, Derom E.
    Acta Clin Belg; 2018 Dec 01; 73(6):413-417. PubMed ID: 29287518
    [Abstract] [Full Text] [Related]

  • 20. Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD.
    Horiike Y, Suzuki Y, Fujisawa T, Yasui H, Karayama M, Hozumi H, Furuhashi K, Enomoto N, Nakamura Y, Inui N, Ogawa N, Suda T.
    Rheumatology (Oxford); 2019 Dec 01; 58(12):2143-2152. PubMed ID: 31143953
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.